Patents by Inventor Elizabeth Punnoose

Elizabeth Punnoose has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
    Publication number: 20180360835
    Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.
    Type: Application
    Filed: September 5, 2018
    Publication date: December 20, 2018
    Applicant: Genentech, Inc.
    Inventors: Kui Lin, Elizabeth Punnoose, Somasekar Seshagiri
  • Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 10092567
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: October 9, 2018
    Assignee: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
    Patent number: 9717730
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: August 1, 2017
    Assignee: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Combinations of AKT and MEK inhibitor compounds, and methods of use
    Patent number: 9682082
    Abstract: The invention provides combinations comprising a) compound of formula I: (formula I), or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: June 20, 2017
    Assignee: GENENTECH, INC.
    Inventors: Brian Lee, Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20170157124
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: February 21, 2017
    Publication date: June 8, 2017
    Applicant: Genentech, Inc.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • Compositions and methods for prostate cancer analysis
    Patent number: 9632091
    Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 25, 2017
    Assignee: GENENTECH, INC.
    Inventors: Siminder Atwal, Jo-Anne Hongo, Mark Lackner, Elizabeth Punnoose, Bonnee Rubinfeld, Rajesh Vij
  • BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
    Publication number: 20170065588
    Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.
    Type: Application
    Filed: August 15, 2016
    Publication date: March 9, 2017
    Inventors: Kui Lin, Elizabeth Punnoose, Somasekar Seshagiri
  • COMPOSITIONS AND METHODS FOR PROSTATE CANCER ANALYSIS
    Publication number: 20160274116
    Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
    Type: Application
    Filed: October 21, 2015
    Publication date: September 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Siminder ATWAL, Jo-Anne HONGO, Mark LACKNER, Elizabeth PUNNOOSE, Bonnee RUBINFELD, Rajesh VIJ
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE
    Publication number: 20160228440
    Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 11, 2016
    Applicant: Genentech, Inc.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND CHEMOTHERAEPTUC AGENTS, AND METHODS OF USE
    Publication number: 20150064171
    Abstract: The invention provides combinations comprising a) compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: March 5, 2015
    Applicant: GENENTECH, INC.
    Inventors: Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath, Jeffrey Wallin, Premal Patel
  • COMBINATIONS OF AKT AND MEK INHIBITOR COMPOUNDS, AND METHODS OF USE
    Publication number: 20140155372
    Abstract: The invention provides combinations comprising a) compound of formula I: (formula I), or a pharmaceutically acceptable salt thereof; and another agent selected from GDC-0973, PD-0325901, or a pharmaceutically acceptable salt thereof. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: March 30, 2012
    Publication date: June 5, 2014
    Applicant: GENENTECH, INC.
    Inventors: Brian Lee, Kui Lin, Michelle Nannini, Elizabeth Punnoose, Deepak Sampath
  • BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
    Publication number: 20140031259
    Abstract: Methods for predicting sensitivity to cancer treatments by assessing biomarkers and combinations of biomarkers include evaluating the presence of mutations to Akt, wherein the presence of said mutations correlates with the sensitivity of Akt inhibitors.
    Type: Application
    Filed: March 30, 2012
    Publication date: January 30, 2014
    Applicant: GENENTECH, INC.
    Inventors: Kui Lin, Elizabeth Punnoose, Somasekar Seshagiri